NR 508 WEEK 3 2026/2027 | NURSING COURSE QUESTIONS & ANSWERS | EXAM-FOCUS…
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 508 Week 3 2026/2027 |
Nursing Course Questions &
Answers | Exam-Focused
Comprehensive Review
(Rationales)
Verified Answers Exam Ready With Rationales 142 QUESTIONS
DOCUMENT OVERVIEW
This comprehensive review document contains 142 exam-focused questions with provided
correct answers and detailed rationales, covering cardiovascular nursing. It is suitable for
in-depth study, thorough course review, and targeted certification preparation.
TOPICS
• Heart Failure Pathophysiology & • Hyperlipidemia Management
Classification
• Gastrointestinal Disorders & • Angina & Antianginal Therapy
Medications
• Hypertension Pathophysiology & • Antihypertensive Agents: ACEI, ARB,
Diuretics CCB
• General Patient Management & • Cardiac Dysrhythmias &
Education Antiarrhythmics
Page 1
, E XA M Q U EST I O N S
Q1 QUESTION 1 OF 142
Angiotensin-converting-enzyme (ACE) inhibitors are a central part of the treatment of heart
failure because they have more than one action to address the pathological changes in this
disorder. Which of the following pathological changes in heart failure is NOT addressed by
ACE inhibitors?
1. Changes in the structure of the left ventricle so that it dilates, hypertrophies, and uses
energy less efficiently.
2. Reduced formation of cross-bridges so that contractile force decreases.
3. Activation of the sympathetic nervous system that increases heart rate and preload.
4. Decreased renal blood flow that decreases oxygen supply to the kidneys.
RESPONSE
3. Activation of the sympathetic nervous system that increases heart rate and preload.
RATIONALE
ACE inhibitors primarily target the renin-angiotensin-aldosterone system (RAAS) to reduce
afterload and preload, thereby mitigating cardiac remodeling. While they indirectly influence
sympathetic tone by reducing RAAS activation, they do not directly counteract the initial
sympathetic nervous system *activation* itself. This direct activation leads to increased heart rate
and preload, which is not the primary effect inhibited by ACE inhibitors.
Q2 QUESTION 2 OF 142
One of the three types of heart failure involves systolic dysfunction. Potential causes of this
most common form of heart failure include:
1. Myocardial ischemia and injury secondary to myocardial infarction
2. Inadequate relaxation and loss of muscle fiber secondary to valvular dysfunction
3. Increased demands of the heart beyond its ability to adapt secondary to anemia
4. Slower filling rate and elevated systolic pressures secondary to uncontrolled
hypertension
RESPONSE
1. Myocardial ischemia and injury secondary to myocardial infarction
Page 2
, RATIONALE
Systolic heart failure is characterized by impaired contractility, leading to reduced ejection
fraction. Myocardial infarction causes myocardial ischemia and injury, directly damaging the
contractile muscle fibers and impairing the heart's ability to pump blood forward effectively, thus
causing systolic dysfunction. Other listed causes are more typically associated with diastolic
dysfunction or increased cardiac workload without primary systolic impairment.
Q3 QUESTION 3 OF 142
The American Heart Association and the American College of Cardiology have devised a
classification system for heart failure that can be used to direct treatment. Patients with
symptoms and underlying disease are classified as stage:
1. A
2. B
3. C
4. D
RESPONSE
3. C
RATIONALE
The AHA/ACC heart failure staging system categorizes risk and disease progression. Stage C
signifies established symptomatic heart failure, where patients exhibit current or prior symptoms
of heart failure (dyspnea, fatigue) along with objective evidence of structural heart disease. This
stage guides the initiation of guideline-directed medical therapy.
Q4 QUESTION 4 OF 142
Diagnosis of heart failure cannot be made by symptoms alone because many disorders share
the same symptoms. The most specific and sensitive diagnostic test for heart failure is:
1. Chest x-rays that show cephalization and measure heart size
2. Two-dimensional echocardiograms that identify structural anomalies and cardiac
dysfunction
3. Complete blood count, blood urea nitrogen, and serum electrolytes that facilitate staging
for end-organ damage
4. Measurement of brain natriuretic peptide to distinguish between systolic and diastolic
dysfunction
Page 3
, RESPONSE
2. Two-dimensional echocardiograms that identify structural anomalies and cardiac
dysfunction
RATIONALE
Two-dimensional echocardiography provides direct visualization of cardiac structure and function,
allowing for accurate identification of anomalies and assessment of ejection fraction. This detailed
anatomical and physiological information is superior to other methods for confirming the presence
and severity of heart failure. Therefore, it serves as the most specific and sensitive diagnostic
modality.
Q5 QUESTION 5 OF 142
Treatments for heart failure, including drug therapy, are based on the stages developed by
the ACC/AHA. Stage A patients are treated with:
1. Drugs for hypertension and hyperlipidemia, if they exist
2. Lifestyle management including diet, exercise, and smoking cessation only
3. Angiotensin-converting enzyme (ACE) inhibitors to directly affect the heart failure only
4. No drugs are used in this early stage
RESPONSE
1. Drugs for hypertension and hyperlipidemia, if they exist
RATIONALE
The ACC/AHA guidelines for heart failure management classify patients into stages to tailor
interventions. Stage A represents individuals at high risk for developing heart failure but without
structural heart disease or symptoms. Treatment focuses on managing existing risk factors such as
hypertension and hyperlipidemia to prevent progression.
Q6 QUESTION 6 OF 142
Class I recommendations for stage A heart failure include:
1. Aerobic exercise within tolerance levels to prevent the development of heart failure
2. Reduction of sodium intake to less than 2,000 mg/day to prevent fluid retention
3. Beta blockers for all patients regardless of cardiac history
4. Treatment of thyroid disorders, especially if they are associated with tachyarrhythmias
Page 4
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 508 Week 3 2026/2027 |
Nursing Course Questions &
Answers | Exam-Focused
Comprehensive Review
(Rationales)
Verified Answers Exam Ready With Rationales 142 QUESTIONS
DOCUMENT OVERVIEW
This comprehensive review document contains 142 exam-focused questions with provided
correct answers and detailed rationales, covering cardiovascular nursing. It is suitable for
in-depth study, thorough course review, and targeted certification preparation.
TOPICS
• Heart Failure Pathophysiology & • Hyperlipidemia Management
Classification
• Gastrointestinal Disorders & • Angina & Antianginal Therapy
Medications
• Hypertension Pathophysiology & • Antihypertensive Agents: ACEI, ARB,
Diuretics CCB
• General Patient Management & • Cardiac Dysrhythmias &
Education Antiarrhythmics
Page 1
, E XA M Q U EST I O N S
Q1 QUESTION 1 OF 142
Angiotensin-converting-enzyme (ACE) inhibitors are a central part of the treatment of heart
failure because they have more than one action to address the pathological changes in this
disorder. Which of the following pathological changes in heart failure is NOT addressed by
ACE inhibitors?
1. Changes in the structure of the left ventricle so that it dilates, hypertrophies, and uses
energy less efficiently.
2. Reduced formation of cross-bridges so that contractile force decreases.
3. Activation of the sympathetic nervous system that increases heart rate and preload.
4. Decreased renal blood flow that decreases oxygen supply to the kidneys.
RESPONSE
3. Activation of the sympathetic nervous system that increases heart rate and preload.
RATIONALE
ACE inhibitors primarily target the renin-angiotensin-aldosterone system (RAAS) to reduce
afterload and preload, thereby mitigating cardiac remodeling. While they indirectly influence
sympathetic tone by reducing RAAS activation, they do not directly counteract the initial
sympathetic nervous system *activation* itself. This direct activation leads to increased heart rate
and preload, which is not the primary effect inhibited by ACE inhibitors.
Q2 QUESTION 2 OF 142
One of the three types of heart failure involves systolic dysfunction. Potential causes of this
most common form of heart failure include:
1. Myocardial ischemia and injury secondary to myocardial infarction
2. Inadequate relaxation and loss of muscle fiber secondary to valvular dysfunction
3. Increased demands of the heart beyond its ability to adapt secondary to anemia
4. Slower filling rate and elevated systolic pressures secondary to uncontrolled
hypertension
RESPONSE
1. Myocardial ischemia and injury secondary to myocardial infarction
Page 2
, RATIONALE
Systolic heart failure is characterized by impaired contractility, leading to reduced ejection
fraction. Myocardial infarction causes myocardial ischemia and injury, directly damaging the
contractile muscle fibers and impairing the heart's ability to pump blood forward effectively, thus
causing systolic dysfunction. Other listed causes are more typically associated with diastolic
dysfunction or increased cardiac workload without primary systolic impairment.
Q3 QUESTION 3 OF 142
The American Heart Association and the American College of Cardiology have devised a
classification system for heart failure that can be used to direct treatment. Patients with
symptoms and underlying disease are classified as stage:
1. A
2. B
3. C
4. D
RESPONSE
3. C
RATIONALE
The AHA/ACC heart failure staging system categorizes risk and disease progression. Stage C
signifies established symptomatic heart failure, where patients exhibit current or prior symptoms
of heart failure (dyspnea, fatigue) along with objective evidence of structural heart disease. This
stage guides the initiation of guideline-directed medical therapy.
Q4 QUESTION 4 OF 142
Diagnosis of heart failure cannot be made by symptoms alone because many disorders share
the same symptoms. The most specific and sensitive diagnostic test for heart failure is:
1. Chest x-rays that show cephalization and measure heart size
2. Two-dimensional echocardiograms that identify structural anomalies and cardiac
dysfunction
3. Complete blood count, blood urea nitrogen, and serum electrolytes that facilitate staging
for end-organ damage
4. Measurement of brain natriuretic peptide to distinguish between systolic and diastolic
dysfunction
Page 3
, RESPONSE
2. Two-dimensional echocardiograms that identify structural anomalies and cardiac
dysfunction
RATIONALE
Two-dimensional echocardiography provides direct visualization of cardiac structure and function,
allowing for accurate identification of anomalies and assessment of ejection fraction. This detailed
anatomical and physiological information is superior to other methods for confirming the presence
and severity of heart failure. Therefore, it serves as the most specific and sensitive diagnostic
modality.
Q5 QUESTION 5 OF 142
Treatments for heart failure, including drug therapy, are based on the stages developed by
the ACC/AHA. Stage A patients are treated with:
1. Drugs for hypertension and hyperlipidemia, if they exist
2. Lifestyle management including diet, exercise, and smoking cessation only
3. Angiotensin-converting enzyme (ACE) inhibitors to directly affect the heart failure only
4. No drugs are used in this early stage
RESPONSE
1. Drugs for hypertension and hyperlipidemia, if they exist
RATIONALE
The ACC/AHA guidelines for heart failure management classify patients into stages to tailor
interventions. Stage A represents individuals at high risk for developing heart failure but without
structural heart disease or symptoms. Treatment focuses on managing existing risk factors such as
hypertension and hyperlipidemia to prevent progression.
Q6 QUESTION 6 OF 142
Class I recommendations for stage A heart failure include:
1. Aerobic exercise within tolerance levels to prevent the development of heart failure
2. Reduction of sodium intake to less than 2,000 mg/day to prevent fluid retention
3. Beta blockers for all patients regardless of cardiac history
4. Treatment of thyroid disorders, especially if they are associated with tachyarrhythmias
Page 4
